Aminoglycosides, toxicity and cystic fibrosis

Watson, Alan R.
June 2007
Journal of the Royal Society of Medicine (Supplement);Jun2007, Vol. 100 Issue 47, p24
Academic Journal
The article focuses on the use of aminoglycosides for the treatment of cystic fibrosis. Aminoglycosides are active against Pseudomonas aeruginosa and synergizes with beta lactum antibiotics which effectively penetrate the sputum. It also discusses why there is little concern about nephrotoxicity of aminoglycosides and its extent in cystic fibrosis patients. A daily dosing of aminoglycosides lead to less nephrotoxicity.


Related Articles

  • Pseudomonas aeruginosa Biofilms in Disease. Mulcahy, Lawrence; Isabella, Vincent; Lewis, Kim // Microbial Ecology;Jul2014, Vol. 68 Issue 1, p1 

    Pseudomonas aeruginosa is a ubiquitous organism that is the focus of intense research because of its prominent role in disease. Due to its relatively large genome and flexible metabolic capabilities, this organism exploits numerous environmental niches. It is an opportunistic pathogen that sets...

  • Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Dales, L.; Ferris, W.; Vandemheen, K.; Aaron, S. D. // European Journal of Clinical Microbiology & Infectious Diseases;Oct2009, Vol. 28 Issue 10, p1275 

    We identified double and triple antibiotic combinations effective against biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa sampled from cystic fibrosis (CF) patients undergoing acute pulmonary exacerbations. Sputum bacteria from 110 CF patients were grown as biofilms. Combination...

  • Gilead Reports Positive Phase III Results On CF Drug; Plans NDA. Shrine, Jim // BioWorld Today;5/31/2007, Vol. 18 Issue 105, p1 

    The article reports on the positive result of the second Phase III trial for aztreonam lysine inhaled antibiotic, which was manufactured by Gilead Sciences Inc. for patients with cystic fibrosis. The antibiotic specifically targets patients who have pulmonary Pseudomonas Aeruginosa infection. A...

  • Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Clancy, J. P.; Dupont, L.; Konstan, M. W.; Billings, J.; Fustik, S.; Goss, C. H.; Lymp, J.; Minic, P.; Quittner, A. L.; Rubenstein, R. C.; Young, K. R.; Saiman, L.; Burns, J. L.; Govan, J. R. W.; Ramsey, B.; Gupta, R. // Thorax;Sep2013, Vol. 68 Issue 9, p818 

    Rationale: Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. Objectives: To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P...

  • Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Gaspar, M.; Couet, W.; Olivier, J.-C.; Pais, A.; Sousa, J. // European Journal of Clinical Microbiology & Infectious Diseases;Oct2013, Vol. 32 Issue 10, p1231 

    Cystic fibrosis (CF) is a complex inherited disease which affects many organs, including the pancreas and liver, gastrointestinal tract and reproductive system, sweat glands and, particularly, the respiratory system. Pseudomonas aeruginosa is the main cause of chronic airway infection. In order...

  • {beta}-Lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). Véronique Dubois; Corinne Arpin; Virginie Dupart; Aline Scavelli; Laure Coulange; Catherine André; Isabelle Fischer; Frédéric Grobost; Jean-Philippe Brochet; Isabelle Lagrange; Brigitte Dutilh; Jacqueline Jullin; Patrick Noury; Gilberte Larribet; Claudine Quentin // Journal of Antimicrobial Chemotherapy (JAC);Aug2008, Vol. 62 Issue 2, p316 

    Objectives The aim of this study was to assess antibiotic resistance rates and mechanisms of β-lactam and aminoglycoside resistance among isolates of Pseudomonas aeruginosa isolated in the extra-hospital setting (community and private healthcare centres). Patients and methods During a 4...

  • Long-term inhaled dry powder mannitol improves lung function in CF.  // Biomedical Market Newsletter;12/21/2011, Vol. 21, p1 

    The article focuses on a new study which revealed the positive aspects of adding inhaled dry powder mannitol to standard therapy for treatment against cystic fibrosis (CF). Moira L. Aitken, professor, University of Washington Medical Center states that the study support the use of inhaled...

  • New therapeutic key for cystic fibrosis: a role for lipoxins. Takai, Daiya; Nagase, Takahide; Shimizu, Takao // Nature Immunology;Apr2004, Vol. 5 Issue 4, p357 

    Suggests the role of lipoxins as a therapeutic key in the management of cystic fibrosis (CF). Development of lung infections with Pseudomonas aeruginosa, which eventually compromises lung function, a hallmark of CF; Identification of the CF Transmembrane conductance regulator (CFTR) as the...

  • Aerosol Antibiotics in Cystic Fibrosis. Geller, David E. // Respiratory Care;May2009, Vol. 54 Issue 5, p658 

    Chronic airways infection and inflammation is the greatest source of morbidity and mortality in cystic fibrosis (CF) patients. Many organisms can be found in the lower respiratory tract of CF patients, but infection with mucoid Pseudomonas aeruginosa is common, is associated with poorer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics